Evidence map›Paper›PMID 35575922›Full record

ReviewAdvances in experimental medicine and biology2022

HDL and Scavenger Receptor Class B Type I (SRBI).

Hong Yu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Dietary effects on the retina of hamsters.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  5. Article
  6. Relationship between Abnormal Lipid Metabolism and Gallstone Formation.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025
    Review
  7. Article
  8. Association betweenBiomedical reports · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Anti-inflammatory effect of ApoE23 onOpen medicine (Warsaw, Poland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hong YuWuhan University School of Basic Medical Sciences, Wuhan, Hubei, China. yu.hong@whu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The scavenger receptor class B type I (SR-BI) is a versatile HDL receptor protein. It is highly expressed in liver and steroidogenic tissues. SR-BI regulates selective uptake of cholesterol ester (CE) from HDL, revealing its role in mediating reverse cholesterol transport (RCT) and steroid hormone synthesis. In addition, SR-BI is involved in cholesterol transport, cellular inflammatory response, platelet reactivity, and HDL-initiated signaling in the vascular system in several mouse models. Mutations in the human SR-BI gene (SCARB1) have been found to be associated with abnormally high plasma HDL-C levels and an increased risk of atherosclerotic cardiovascular disease. At present, the key regions of SR-BI transmembrane structure and the regulatory mechanisms of SR-BI expression still need to be further studied. In this chapter, the structural, functional, and regulatory characteristics of SR-BI are reviewed, and the importance of SR-BI in related metabolic diseases was expounded.

Indexed as

CD36 AntigensCholesterol, HDLReceptors, ImmunologicAnimalsCarrier ProteinsCholesterol EstersLiverMiceCarrier ProteinsCD36 AntigensCholesterol EstersCholesterol, HDLReceptors, ImmunologicAtherosclerotic cardiovascular diseaseCellular inflammatory responseCholesterol transportHDL-initiated signalingHDL metabolismPlatelet reactivityReverse cholesterol transportScavenger receptor class B type I (SR-BI)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.